The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

作者：Juan Zhou, Martha E. Shenton, John M. Kane, Diana O. Perkins, Ángela Núñez, Vijay A. Mittal, Rocío Mayol-Troncoso, Johanna M. Jarcho, Leslie E. Horton, Ayşenil Belger, Kerstin Langbein, Julian Wenzel, Fred W. Sabb, Pablo A. Gaspar, Carla Gerber, David R. Roalf, Kristin S. Cadenhead, John D. Cahill, Jack D. Rogers, Ofer Pasternak, Sylvain Bouix, Sung‐Wan Kim, Christy Lai Ming Hui, Lauren M. Ellman, Jason Schiffman, Ivy F. Tso, Bjørn H. Ebdrup, Andrey Anohkin, Jimmy Choi, Joseph Kambeitz, Cheryl M. Corcoran, Yi Nam Suen, Philippe Conus, Clarice Lee, Margaret Niznikiewicz, Lauren Addamo, Jesús Pérez, Steven M. Silverstein, Elizabeth A. Martin, Minah Kim, Eric Chen, Michael J. Coleman, Dominic Dwyer, Daniel Mamah, Stefan Smesny, Muhammad A. Parvaz, Raoul Jenni, Jun Soo Kwon, Tashrif Billah, Daniel H. Mathalon, Patrick D. McGorry, Brian J. Roach, Monica E. Calkins, Thomas J. Whitford, Godfrey D. Pearlson, XiaoChen Tang, Zailyn Tamayo, Ilvana Dzafic, Igor Izyurov, Judy L. Thompson, Oliver Pogarell, Tianhong Zhang, Lana Kambeitz‐Ilankovic, Barnaby Nelson, Nikolaos Koutsouleris, Juan Montalvo, Gregory P. Strauss, Albert R. Powers, Stephen J. Wood, Rachel A. Rabin, Paolo Fusar‐Poli, Merete Nordentoft, Matthew R. Broome, Swapna Verma, Scott W Woods, Rachel Upthegrove, Nicholas J. K. Breitborde, Tristán Bekinschtein, Stewart A. Shankman, Michael C. Stevens, Nicole C. Swann, Holly Hamilton, Louise Birkedal Glenthøj, Kate Buccilli, Ricardo E. Carrión, Rolando I Castillo-Passi, Matcheri S. Keshavan, William S. Stone, Carrie E. Bearden, Barbara A. Cornblatt, René S. Kahn, Jean Addington, Kang-Ik K. Cho, Anna Jo, Gregory A. Light, Jijun Wang, Dean F. Salisbury, Sarah Kerins, Stefano Damiani, Covadonga M. Díaz‐Caneja, Suzie Lavoie, Luis Alameda, Celso Arango, Spero Nicholas, Daniel H. Wolf, Riaz Shaik, Jai Shah · 发表于：UNC Libraries · 年份：2025 · DOI：10.17615/6zhr-cn47 · 研究领域：Neural and Behavioral Psychology Studies、EEG and Brain-Computer Interfaces、Neuroscience and Music Perception

Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49–0.85; CON: mean = 0.71, range = 0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and v...